Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer
- 294 Downloads
Background Src has a critical role in tumor cell migration and invasion. Increased Src activity has been shown to correlate with disease progression and poor prognosis, suggesting Src could serve as a therapeutic target for kinase inhibition. Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor. Methods Metastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study. Saracatinib was administered at 175 mg by mouth daily for 28 day cycles until dose-limiting toxicity or progression as determined by staging every 2 cycles. The primary endpoint was improvement in 4 month progression-free survival. Design of Thall, Simon, and Estey was used to monitor proportion of patients that were progression free at 4 months. The trial was opened with plan to enroll maximum of 35 patients, with futility assessment every 10 patients. Results A total of 10 patients were enrolled between January and November 2007. Further enrollment was stopped due to futility. Median progression-free survival was 7.9 weeks, with all 10 patients showing disease progression following radiographic imaging. Median overall survival was 13.5 months. All patients were deceased by time of analysis. Observed adverse events were notable for a higher than expected number of patients with grade 3 hypophosphatemia (n = 5). Conclusion Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.
KeywordsSaracatinib Src inhibitor Colorectal cancer Phase 2 AZD0530 Colon cancer Src kinase
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This study was presented at AACR 2008 and funded by the National Cancer Institute (NCI Protocol #7565, NSC735464).
- 1.Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA: Cancer J Clin 64(2):104–17Google Scholar
- 5.Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol : Off J Am Soc Clin Oncol 27(5):672–80CrossRefGoogle Scholar
- 7.Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res : Off J Am Assoc Cancer Res 17(20):6522–30CrossRefGoogle Scholar
- 12.Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS et al (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24(19):3110–20PubMedCrossRefGoogle Scholar
- 18.Investigator’s Brochure AZD0530 (2005) In: AstraZeneca Pharmaceuticals M, Cheshire, EnglandGoogle Scholar
- 19.Hennequin L, Allen J, Costello GF et al (2005) The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc Am Assoc Cancer Res 46:A2537Google Scholar
- 22.Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K et al (2012) A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investig New Drugs 30(3):1158–63CrossRefGoogle Scholar
- 24.Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anti-Cancer Drugs 20(3):179–84PubMedCentralPubMedCrossRefGoogle Scholar
- 25.Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A et al (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11(5):306–11PubMedCentralPubMedCrossRefGoogle Scholar
- 26.Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD et al (2014) A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer 85(2):245–50PubMedCrossRefGoogle Scholar
- 27.Messersmith WA NS, Arcaroli J et al. (2010) A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic paancreatic cancer. Journal of Clinical Oncology. Suppl: abstr e14515Google Scholar
- 28.Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L et al (2014) A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer 15(1):52–7PubMedCrossRefGoogle Scholar
- 30.McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M et al (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 25(10):1988–95CrossRefGoogle Scholar
- 37.Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C et al (2014) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investig New Drugs 32(2):330–9CrossRefGoogle Scholar
- 38.Lieu C, Wolff RA, Eng C et al. (2010) Phase 1B study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(15 suppl): Abstract 3536Google Scholar
- 39.Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E et al (2012) Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol : Off J Eur Soc Med Oncol / ESMO 23(3):610–7CrossRefGoogle Scholar
- 40.Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T et al (2014) Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist 19(4):348–9PubMedCentralPubMedCrossRefGoogle Scholar